Cargando…
Emerging targets for drug addiction treatment /
In this book the editor presents a collection of state-of-the-art, authoritative overviews in the field of treatment for drug and behavioral addictions. Both clinical and basic research perspectives are integrated in the book, covering recent findings in the field of stimulant, cannabis and opioid a...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Hauppauge, N.Y. :
Nova Science Publisher's,
2012.
|
| Colección: | Substance abuse assessment, interventions and treatment series.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; EMERGING TARGETS FOR DRUG ADDICTION TREATMENT; Library of Congress Cataloging-in-Publication Data; CONTENTS; INTRODUCTION; Chapter 1: PHARMACOLOGICAL TREATMENTS FOR COCAINE ADDICTION; ABSTRACT; 1. EPIDEMIOLOGICAL DATA; 2. CLINICAL DATA; 2. PHARMACOLOGICAL TREATMENTS; 2.1. Abstinence Initiation; 2.1.1. N-Acetylcysteine; 2.1.2. Vigabatrin; 2.1.3. Modafinil; 2.1.4. Varenicline; 2.1.5. Antidepressants; 2.2. Relapse Prevention Medication; 2.2.1. Disulfiram; 2.2.2. Topiramate; 2.2.3. Baclofen; 2.2.4. Dextroamphetamine (D-Amphetamine)
- 2.2.5. Cocaine VaccineCONCLUSION; STATEMENT OF INTEREST; REFERENCES; Chapter 2: STIMULANTS: NEUROIMAGING AND TREATMENTS; ABSTRACT; 1. INTRODUCTION; 2. STIMULANTS; 2.1. Cocaine; 2.2. Amphetamine-Type Stimulants; 3. NEUROIMAGING; 3.1. Positron Emission Tomography; 3.1.1. Cocaine; 3.1.2. Methamphetamine; 3.2. Magnetic Resonance Imaging; 3.2.1. Functional MRI; 3.2.1.1. Cocaine; 3.2.1.2. Methamphetamine; 3.2.2. Structural MRI; 3.2.2.1. Cocaine; 3.2.2.2. Methamphetamine; 3.2.3. Diffusion Tensor Imaging; 3.2.3.1. Cocaine; 3.2.3.2. Methamphetamine; 3.2.4. Magnetic Resonance Spectroscopy
- 3.2.4.1. Cocaine3.2.4.2. Amphetamine; 3.2.4.3. Methamphetamine; 4. PHARMACOLOGICAL TREATMENTFOR STIMULANT ADDICTION; 4.1. Agonist Replacement Therapy; 4.2. Dopamine-Modulating Agents; 4.3. GABA-Modulating Agents; 4.3.1. Baclofen; 4.3.2. Gabapentin; 4.3.3. Vigabatrin; 4.4. Glutamate-Modulating Agents; 4.5. Serotonin- and Noradrenaline-Modulating Agents; 4.5.1. Selective Serotonin Reuptake Inhibitors; 4.5.2. Mirtazapine; 4.5.3. Bupropion; 4.6. Opioid Antagonists; CONCLUSION; REFERENCES; Chapter 3: IMMUNOTHERAPEUTIC VACCINES FOR SUBSTANCE ABUSE; ABSTRACT; 1. INTRODUCTION; 2. CONJUGATE VACCINES
- 3. ANTIBODY BINDING4. ANTIBODY INHIBITION OF DRUG ACTION; 5. MORPHINE; 6. COCAINE; 7. METHAMPHETAMINE; CONCLUSION; REFERENCES; Chapter 4: DEVELOPMENTS IN OPTIMIZING TREATMENT OF OPIOID ADDICTION: A SHORT OVERVIEW; ABSTRACT; 1. INTRODUCTION; 2. QUALITY; 2.1. Deficiencies; 2.2. Normative Standards; 2.3. Evidence Based Best Practice; 2.4. Assessment Instruments; 3. COVERAGE IMPROVEMENT; 3.1. Integrative Approaches; 3.2. Coverage Improvement: Diversification; 3.3. Coverage Improvement: Training Systems; 3.4. Coverage Improvement: Changing the Paradigm; REFERENCES
- Chapter 5: CANNABIS USE DISORDER: EPIDEMIOLOGY, MANAGEMENT AND FUTURE DIRECTIONSABSTRACT; 1. EPIDEMIOLOGY OF CANNABIS USE; 2. NATURAL HISTORY OF CANNABIS USE; 3. CANNABIS USE DISORDERS; 4. TREATMENT SEEKING; 5. INTERVENTIONS FOR CANNABIS USE DISORDER; 5.1. Evidence for Cannabis Treatment among Adults; 5.2. Psychological Interventions; 5.3. Pharmacotherapy for Cannabis Use Disorders; 5.4. Treatments for Special Populations; 5.4.1. Adolescents; 5.4.2. What is Available for Those with Serious Mental Health Problems?; CONCLUSION; REFERENCES